GlassScriptPhysician profile
Louis M Stephens
NPI 1528001161
$7,249.20
in general payments reported to CMS, 2019-2025
41 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $270 · 2021: $212 · 2022: $1,047 · 2023: $1,634 · 2024: $1,896 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,062.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,552.59 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $812.17 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $789.31 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $446.59 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $426.63 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $387.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.78 | 2022-2025 | Xifaxan |
| Abbott Laboratories | $236.71 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $209.52 | 2019-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $201.69 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $177.13 | 2019-2024 | |
| Pfizer INC. | $170.01 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.61 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $159.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $126.59 | 2021-2024 | Dexcom G6 Transmitter |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $123.55 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $119.21 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $105.08 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $81.54 | 2019-2024 | Veozah |
| Daiichi Sankyo INC. | $76.00 | 2022-2024 | Injectafer |
| Allergan, INC. | $74.29 | 2019-2020 | |
| Lundbeck LLC | $62.25 | 2024-2025 | Vyepti, Rexulti |
| Abiomed | $54.11 | 2024-2025 | Impella |
| Biohaven Pharmaceutical Holding Company LTD. | $46.12 | 2022 | |
| Merck Sharp & Dohme LLC | $43.37 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Esperion Therapeutics, INC. | $34.34 | 2021-2022 | |
| Corcept Therapeutics | $33.75 | 2024 | Korlym |
| Amarin Pharma, INC. | $31.83 | 2019 | |
| Medtronic, INC. | $25.65 | 2024 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $24.59 | 2019 | |
| Inari Medical, INC. | $22.83 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Axsome Therapeutics, INC. | $22.02 | 2024 | Auvelity |
| Tris Pharma INC | $20.76 | 2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $20.16 | 2024 | Fanapt, Hetlioz |
| Mylan Specialty L.P. | $16.61 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.31 | 2024 | Quviviq |
| Bioventus LLC | $13.15 | 2022 | |
| Promius Pharma LLC | $12.17 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.71 | 2022 | |
| Organon LLC | $8.46 | 2025 | Nexplanon |
| Dynavax Technologies Corporation | $6.50 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.